Degron Therapeutics, MSD R&D, and the Next Generation of Molecular Glue Degraders
Degron Therapeutics, a China‑based pioneer in protein‑degradation therapies, today announced the signing of a Letter...
TPD
PolyMed Biopharmaceuticals Completes Pre‑A++ Funding Round Led by Caleb Capital, Fuels PROTAC‑Focused Pipeline
PolyMed Biopharmaceuticals Co., Ltd., a Chinese‑based, internationally‑oriented biopharma innovator, announced the successful closure of its...
Zennova & Rapafusyn Forge Alliance to Accelerate Non‑Degrading Molecular Glue Therapies
Zennova Pharmaceutical announced today a strategic partnership with U.S.‑based biotech Rapafusyn Pharmaceuticals to jointly develop...
Pfizer and Arvinas Pass Commercial Rights of Vepdegestrant to Third Party
Pfizer Inc. (NYSE: PFE) and Arvinas, Inc. (NASDAQ: ARVN) announced that they are stepping back...
Monte Rosa Therapeutics and Novartis Partner on Degrader Development
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) announced today a new collaboration with Novartis (NYSE: NVS)...
Haisco Secures FDA Clinical Trial Approval for First‑In‑Class BCL6 PROTAC HSK47977
Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that the U.S. Food and Drug Administration...
Zennova & Rapafusyn Forge BioCarier‑Powered RapaGlue Collaboration – 2025
Zennova Pharmaceuticals Group and Rapafusyn Pharmaceuticals on Aug. 28, 2025 announced a strategic collaboration to...
XtalPi Collaborates with Dong-A ST on AI-Driven Drug Discovery for Immunological Diseases
Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228) and Korea’s leading pharmaceutical company, Dong-A...
Sino Biopharmaceutical’s TQB3142 IND Application Accepted by China’s NMPA for Malignant Tumor Treatment
Sino Biopharmaceutical Limited (HKG: 1177) announced that the Investigational New Drug (IND) application for TQB3142,...
Arvinas and Pfizer’s Vepdegestrant NDA Accepted by FDA for ER+/HER2- Breast Cancer
Arvinas, Inc. (NASDAQ: ARVN) and its partner Pfizer (NYSE: PFE) announced on August 8, 2025,...
Kymera and Sanofi Advance IRAK4 Program With Selection of KT-485 for Clinical Development
US-based Kymera Therapeutics Inc. (NASDAQ: KYMR) announced updates to its IRAK4-targeted program collaboration with Sanofi....
Gilead Signs Licensing Pact With Kymera Therapeutics for CDK2-Targeted MGD
US major Gilead Sciences, Inc. (NASDAQ: GILD) this week entered into an exclusive option and...
Nurix Therapeutics Announces Sanofi’s Acquisition of STAT6 Program Rights
US-based Nurix Therapeutics, Inc. (NASDAQ: NRIX) announced that Sanofi (NASDAQ: SNY), a major French pharmaceutical...
Genentech and Orionis Enter Second Collaboration on Small-Molecule Oncology Drugs
Genentech, a subsidiary of Swiss pharmaceutical leader Roche (SWX: ROG, OTCMKTS: RHHBY), this week entered...
Sino Biopharma’s TQB3019 Gains NMPA Approval for Hematological Malignancies
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received clinical approval from the...
Arvinas and Pfizer Announce Positive Phase III Results for Vepdegestrant in ER+/HER2- Breast Cancer
Partners Arvinas, Inc. (NASDAQ: ARVN) and Pfizer Inc. (NYSE: PFE) announced positive topline results from...
Magnet Biomedicine and Eli Lilly Partner on Molecular Glue Therapeutics
US-based molecular glue specialist Magnet Biomedicine has entered into a collaboration and license agreement with...
Joyo Pharma’s JYP0015 Receives CDE Approval for RAS Mutation Cancer Trials
China’s Center for Drug Evaluation (CDE) has tacitly approved Joyo Pharma’s Category 1 drug JYP0015,...
PolyMed Biopharma Licenses HPB-143 to Photys Therapeutics for Global Development
PolyMed Biopharma, a Hangzhou-based developer of Proteolysis Targeting Chimera (PROTAC) drugs, has entered into a...
Degron Therapeutics’ DEG6498 Receives FDA Clearance for Clinical Trials
China-based Degron Therapeutics, a developer of molecular glue-based drugs, announced that the U.S. Food and...